Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 1/2 3Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 14Gastrointestinal 5Head & Neck 4Sarcoma 3Genitourinary 3CNS 3Gynecologic 1Dermatologic 1Breast 1

Conditions

Prostatic Neoplasms 1Non-Metastatic Prostate Cancer 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Brain Neoplasms 1

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Gefitinib × Genitourinary × Clear all
NCT00085566 2016-01-20

Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
61 enrolled 8 charts
CNSGenitourinarySarcoma

Brain Neoplasms, Glioblastoma, Prostatic Neoplasms, Central Nervous System Neoplasms, Gliosarcoma

NCT00113529 2011-08-29

Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma

Pfizer

Phase 1/2 Completed
42 enrolled 35 charts
Genitourinary

Carcinoma, Renal Cell

NCT00239291 2009-04-23

Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer

AstraZeneca

Phase 1/2 Completed
42 enrolled
Genitourinary

Non-Metastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡